EyePoint Q3 net loss $29.4M; positive DURAVYU interim data, $161M equity financing

EyePoint, Inc.

2024-Q3 EPS reported -$1.67 revenue$31,685,000

Q3 net loss $29.4M ($0.54 per share) vs. $12.6M loss a year ago; revenue $10.5M down from $15.2M.
Interim Phase 2 VERONA data: DURAVYU 2.7mg showed +8.9 BCVA letters and -68 μm CST improvement at 16 weeks vs. aflibercept.
First patient dosed in Phase 3 LUGANO trial for wet AMD; second Phase 3 LUCIA first patient dosing expected by end of 2024.
Completed $161M oversubscribed public equity offering at $11.00/share; cash runway extended into 2027.
Opened 40,000 sq ft cGMP commercial manufacturing facility in Northbridge, MA for DURAVYU.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.